In addition, plasmabiomarkers of neurohormonal regulation, fibrosis and inflammation (such asN-Terminal pro-B type natriuretic peptide, sST2, interleukin-6 [IL6], troponinand c-reactive-protein) may also be important for SCD risk stratification [13].Thus, studies are needed for SCD risk stratification in IHD patients without lowLVEF, focusing on the combined assessment of novel modalities described above, aswell as on the identification of new genetic/epigenetic markers (Fig. 3). The gene discussed is CRP; the disease is Schnyder corneal dystrophy.